Scholar Rock Holding (STU:2QK) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2QK Scholar Rock Holding Corp STU:2QK
34 GF Score
Price €42.84
GF Value €24.41
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Scholar Rock Holding Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:2QK
34GF Score
Scholar Rock Holding Corp STU:2QK
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Scholar Rock Holding (STU:2QK) Overvalued in 2026?

Based on GuruFocus' analysis, Scholar Rock Holding stock appears to be overvalued. The current stock price of €42.84 is trading 75.5% above its estimated GF Value™ of €24.41. GuruFocus considers Scholar Rock Holding to be Significantly Overvalued.

Key valuation signals for STU:2QK:

  • Dividends Received:
  • GF Value™: €24.41 vs. price of €42.84 (75.5% above fair value)
  • GF Score™: 34/100 with 4 warning signs

No single metric tells the full story. See the STU:2QK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scholar Rock Holding Business Description

Other Exchanges SRRK:USA
Address 301 Binney Street, 3rd Floor, Cambridge, MA, USA, 02142
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
34GF Score

Get the complete analysis for STU:2QK

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€42.84
Price
€24.41
GF Value